Peter Humaidan: APHRODITE Criteria to Move Towards a Stratified Gonadotropin Stimulation in Infertile Males
Peter Humaidan, Clinical Director at pMorph Ltd, shared a post on LinkedIn about a paper published in Human Reproduction:
“Treatment of male infertility has until now mostly relied on the empirical use of oral agents to boost spermatogenesis, a fragmented approach resulting in a lack of cohesive strategy, and a high proportion of untreated males. The oral treatment usually results in suboptimal results – the reason why oral treatment for ovarian stimulation in standard IVF was abandoned years ago in women.
Since ICSI was introduced, the interest in boosting spermatogenesis has been very limited in the belief that ICSI solves everything – and we are treating women for their partners problems, which is quite unique in medicine. Time has come to challenge the old dogma and see the infertile male as a patient, rather than a semen sample, and explore his life style, medication, anatomy, and possible exposure to environmental toxicants.
In this context Sandro Esteves and I, very recently published an Opinion paper in HR, using the new APHRODITE criteria to move towards a stratified gonadotropin stimulation in infertile males fulfilling the suggested criteria. Clearly we now need the prospective trials in well defined patient phenotypes, showing the efficacy of gonadotropin stimulation.
Once again- the infertile male is more than a semen sample – he is a patient, deserving the full attention of the IVF doctor, and we call for ‘Male fertility awareness’ as the new ‘mantra’.”
Title: From tablets to targeted therapy: the APHRODITE era in male infertility
Authors: Sandro C Esteves, Peter Humaidan
Stay updated on all scientific advances in the field of fertility with Fertility News.
-
Nov 2, 2026, 17:08Elena Milner: The 2nd Class of the School of Embryology Is Already in Full Swing
-
Nov 2, 2026, 17:05November Is National Diabetes Month – PCOS Awareness Association
-
Nov 2, 2026, 17:04Thanos Papathanasiou: Are We Preparing Patients for the IVF Cycle, or for the IVF Journey?
-
Nov 2, 2026, 17:02Anna Morales: Why Is It So Hard to Build in Women’s Health?
-
Nov 2, 2026, 16:59Rickard Ericsson: Honored to Take on the Role of Interim CEO of the Vitrolife Group
-
Nov 2, 2026, 16:56Mohammed Nasur: 1 Small Simulation, A Bigger Purpose
-
Nov 2, 2026, 16:54Carlos Guerrero: Presenting Our Latest Research on AI and Embryo Assessment at ASRM 2026
-
Nov 2, 2026, 16:52Sarah Lewen: My 1st ASRM Is Officially Complete
-
Nov 2, 2026, 16:49Jemma Garratt: Taking on the Role of Kind IVF and Data Science Manager at London Women’s Clinic